In Brief: PFS incontinence therapy
This article was originally published in The Gray Sheet
Executive Summary
PFS incontinence therapy: Health Care Financing Administration affirms its policy of not reimbursing pelvic floor stimulation incontinence therapy, according to Empi, which had sought a national coverage decision. Empi, the manufacturer of the Innova PFS device, notes that PFS is reimbursed only on an "individual appeal basis." Empi maintained that PFS' clinical efficacy is supported by an updated version of the HHS Agency for Health Care Policy & Research urinary incontinence clinical practice guideline, which recommended use of behavioral interventions such as PFS as first-line treatment of urinary incontinence in most cases ("The Gray Sheet" March 18, I&W-12). Empi plans to continue to pursue a change in policy as more data become available on clinical efficacy and cost effectiveness of the technology...
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.